FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :Rabbit Polyclonal Antibody
Specificity :Recognizes the HDAC2 protein
Cited Applications :WB
Cross Reactivity :Western blot of HDAC2 from human and mouse cells
HDAC2 from other species may also be detectable.
Immunogen :Protein Code Q92769
Formulation :TBS, 50% glycerol
Purification :Affinity Chromatography
Stability :Store at 4°C (add 0.1% NaN3) for several months, and at -20°C for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For optimal performance, avoid repeated handling and multiple freeze/thaw cycles.
Sample Data :Representative western blot (1:1000) with Anti-HDAC2 using 30 µg, 10 µg, 30µg of Hela cell lysate.
Scientific Background :Acetylation of the histone tail causes chromatin to adopt an “open” conformation, allowing trans factors increased accessibility to DNA. The identification of histone acetyltransferases (HATs) and their large multiprotein complexes has yielded important insights into how these enzymes regulate transcription (1,2). HAT complexes interact with sequence-specific activator proteins to target specific genes. In addition to histones, HATs can acetylate non-histone proteins, suggesting multiple roles for these enzymes (3). In contrast, histone deacetylation promotes a “closed” chromatin conformation and typically leads to repression of gene activity (4). Mammalian histone deacetylases can be divided into three classes on the basis of their similarity to various yeast deacetylases (5). Class I (HDACs 1, 2, 3 and 8) proteins are related to the yeast Rpd3-like proteins, those in class II (HDACs 4, 5, 6, 7, 9 and 10) are related to yeast Hda1-like proteins and class III proteins are related to the yeast protein Sir2. Inhibitors of HDAC activity are now being explored as potential therapeutic cancer agents (6,7).
1. Marmorstein, R. et al. (2001) Cell. Mol. Life Sci. 58, 693–703.
2. Gregory, P.D. et al. (2001) Exp. Cell Res. 265, 195–202.
3. Liu, Y. et al. (2000) Mol. Cell. Biol. 20, 5540–5543.
4. Cress, S.D. and Seto, E. (2000) J. Cell. Physiol. 184, 1–16.
5. Gray, S.G. and Ekstrom, T.J. (2001) Exp. Cell Res. 262, 75–83.
6. Thiagalingam, S. et al. (2003) Ann. N. Y. Acad. Sci. 983, 84–100.
7. Viguishin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205–218.
Product Sheets (By Lot #) :
Research Areas :Cardiovascular Disease, WNT Signaling, Cardiovascular Disease, WNT Signaling